LIVIVO - Search results -

Search results

Result 1 - 10 of total 115

Search options

Book: Management of hepatitis C/HIV coinfection in the era of highly effective hepatitis C virus direct-acting antiviral therapy

Wyles, David L.

(Clinical infectious diseases ; volume 63, supplement 1 (15 July 2016))

2016

Author's details	guest editors: David L. Wyles, MD
Series title	Clinical infectious diseases ; volume 63, supplement 1 (15 July 2016)
Collection
Language	English
Size	S23 Seiten, Illustrationen
Publisher	Oxford University Press
Publishing place	Cary, NC
Publishing country	United States
Document type	Book
HBZ-ID	HT019210539
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
Zs A 1505 -63,Suppl.1-	not available for loan	Zeitschriften-Lesesaal

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Don't Put Off Until Tomorrow What You Can Do Today: Hospital Admissions as an Opportunity to Treat Hepatitis C.

Rowan, Sarah E / Wyles, David L

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

2023 Volume 78, Issue 3, Page(s) 591–593

MeSH term(s)	Humans ; Drug Users ; Hepatitis C/drug therapy ; Hepatitis C/epidemiology ; Hepacivirus/genetics ; Hospitalization ; Hospitals
Language	English
Publishing date	2023-11-21
Publishing country	United States
Document type	Editorial ; Comment
ZDB-ID	1099781-7
ISSN	1537-6591 ; 1058-4838
ISSN (online)	1537-6591
ISSN	1058-4838
DOI	10.1093/cid/ciad712
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1505: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 480: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Antiretroviral Effects on HBV/HIV Co-infection and the Natural History of Liver Disease.

Wyles, David L

Clinics in liver disease

2019 Volume 23, Issue 3, Page(s) 473–486

Abstract: Hepatitis B virus (HBV) coinfection is common in persons with human immunodeficiency virus (HIV) infection, contributing significantly to morbidity and mortality. Many currently used HIV antiretroviral therapy (ART) regimens provide potent anti-HBV ... ...

Abstract	Hepatitis B virus (HBV) coinfection is common in persons with human immunodeficiency virus (HIV) infection, contributing significantly to morbidity and mortality. Many currently used HIV antiretroviral therapy (ART) regimens provide potent anti-HBV activity and it is recommended that HBV-HIV coinfected persons be treated with ART regimens containing tenofovir. ART has multiple benefits, including increasing rates of HBV clearance after initial infection and potent suppression of HBV DNA in chronic infection. Nevertheless, long-term studies have yet to demonstrate a profound positive impact of ART on HBV-related fibrosis progression and development of endstage liver disease.
MeSH term(s)	Anti-Retroviral Agents/therapeutic use ; Coinfection/diagnosis ; Coinfection/drug therapy ; Coinfection/epidemiology ; DNA, Viral/drug effects ; Disease Progression ; Female ; HIV/drug effects ; HIV/isolation & purification ; HIV Infections/diagnosis ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; Hepatitis B virus/drug effects ; Hepatitis B virus/isolation & purification ; Hepatitis B, Chronic/diagnosis ; Hepatitis B, Chronic/drug therapy ; Hepatitis B, Chronic/epidemiology ; Humans ; Liver Cirrhosis/epidemiology ; Liver Cirrhosis/pathology ; Liver Cirrhosis/virology ; Male ; Prevalence ; Prognosis ; Risk Assessment ; Survival Analysis ; Tenofovir/therapeutic use ; Treatment Outcome
Chemical Substances	Anti-Retroviral Agents ; DNA, Viral ; Tenofovir (99YXE507IL)
Language	English
Publishing date	2019-05-24
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1472315-3
ISSN	1557-8224 ; 1089-3261
ISSN (online)	1557-8224
ISSN	1089-3261
DOI	10.1016/j.cld.2019.04.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Se 1870: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: CROI 2021: Viral Hepatitis and Other Forms of Liver Injury Impacting People with HIV.

Luetkemeyer, Anne F / Wyles, David L

Topics in antiviral medicine

2021 Volume 29, Issue 3, Page(s) 379–385

Abstract: At the 2021 Conference on Retroviruses and Opportunistic Infections, there was a focus on progress toward hepatitis C virus (HCV) microelimination in geographic regions and targeted populations. HCV elimination is facilitated by well-tolerated, highly ... ...

Abstract	At the 2021 Conference on Retroviruses and Opportunistic Infections, there was a focus on progress toward hepatitis C virus (HCV) microelimination in geographic regions and targeted populations. HCV elimination is facilitated by well-tolerated, highly effective HCV treatment that requires essentially no on-treatment monitoring in most patients, as highlighted by the MINMON (Minimal Monitoring Study or A5360) study, and that should be increasingly available to children with new data supporting feasible treatment in younger patients. Challenges to HCV elimination include HCV reinfection via sexual exposure in men who have sex with men (MSM) and continued barriers to diagnosis and access to HCV treatment. Hepatitis B virus (HBV) suppression may take years in HIV/HBV-coinfected patients. This may have important consequences as the risk for hepatocellular carcinoma was associated in a dose-dependent manner with HBV viral load and was lowest in those with sustained undetectable HBV, highlighting the need for HBV DNA monitoring during therapy. Public health programs should prioritize improving hepatitis A and hepatitis B vaccination in at-risk populations, including people with HIV, as vaccinations rates for these preventable diseases continue to be suboptimal in many settings. Fatty liver disease, heavy alcohol use, antiretroviral therapy, and COVID-19 infection were also examined as drivers of hepatic disease in HIV infection.
MeSH term(s)	Biomedical Research ; Congresses as Topic ; HIV Infections/complications ; Hepatitis A/complications ; Hepatitis B/complications ; Hepatitis C/complications ; Hepatitis, Viral, Human/complications ; Homosexuality, Male ; Humans ; Liver/injuries ; Male
Language	English
Publishing date	2021-08-02
Publishing country	United States
Document type	Journal Article
ZDB-ID	2656632-1
ISSN	2161-5853 ; 2161-5853
ISSN (online)	2161-5853
ISSN	2161-5853
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Resistance to DAAs: When to Look and When It Matters.

Wyles, David L

Current HIV/AIDS reports

2017 Volume 14, Issue 6, Page(s) 229–237

Abstract: Purpose of review: This review provides an overview of HCV resistance-associated substitutions (RASs) with a focus on NS3 protease and NS5A inhibitor resistance. Treatment approaches for managing resistance are also covered including the use of newly ... ...

Abstract	Purpose of review: This review provides an overview of HCV resistance-associated substitutions (RASs) with a focus on NS3 protease and NS5A inhibitor resistance. Treatment approaches for managing resistance are also covered including the use of newly approved therapies with improved resistance profiles. Recent findings: HCV RASs are frequently selected if the patient is not cured during treatment; NS5A RASs persist for prolonged periods of time (years) after treatment failure and may adversely impact retreatment responses. Newly approved regimens with improved potency and resistance profiles are less impacted by resistance and provide the best retreatment options for patients who previously failed DAA therapy. The clinical impact of HCV RASs has been lessened significantly with the introduction of new DAA treatment regimens. Routine testing for resistance is unlikely to impact retreatment approaches if newer regimens are accessible. Knowledge of factors, such as the presence of cirrhosis and prior treatment regimens, remain as the key to optimizing retreatment approaches.
MeSH term(s)	Amino Acid Substitution ; Antiviral Agents/therapeutic use ; Drug Resistance, Viral ; Hepacivirus/drug effects ; Hepacivirus/genetics ; Hepatitis C, Chronic/diagnosis ; Hepatitis C, Chronic/drug therapy ; Humans ; Viral Nonstructural Proteins/antagonists & inhibitors ; Viral Nonstructural Proteins/genetics
Chemical Substances	Antiviral Agents ; NS3 protein, hepatitis C virus ; Viral Nonstructural Proteins ; NS-5 protein, hepatitis C virus (EC 2.7.7.48)
Language	English
Publishing date	2017-11-06
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2151206-1
ISSN	1548-3576 ; 1548-3568
ISSN (online)	1548-3576
ISSN	1548-3568
DOI	10.1007/s11904-017-0369-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5920: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Re-treatment of Hepatitis C Infection After Multiple Failures of Direct-Acting Antiviral Therapy.

Fierer, Daniel S / Wyles, David L

Open forum infectious diseases

2020 Volume 7, Issue 4, Page(s) ofaa095

Abstract: Background: Direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) result in initial cure rates of 95% to 99% and re-treatment cure rates of 95%. Nevertheless, given the sheer magnitude of infected persons, some will ultimately fail ... ...

Abstract	Background: Direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) result in initial cure rates of 95% to 99% and re-treatment cure rates of 95%. Nevertheless, given the sheer magnitude of infected persons, some will ultimately fail multiple DAA therapies, and re-treatment of these persons has not been adequately studied. Methods: We evaluated treated an HIV-infected man with cirrhosis from genotype 1b HCV who had failed 3 DAA regimens. Results: We treated and cured our "particularly difficult-to-cure" patient with sofosbuvir plus glecaprevir/pibrentasvir plus ribavirin for 24 weeks. We discuss the literature on potential biological factors behind his treatment failures such as lack of HCV seroconversion during his infection course, and multiple failures of hepatitis B seroconversion after vaccination, and the rationale for choosing his curative salvage regimen. Discussion: There are no clinical trials-proven re-treatment regimens for "particularly difficult-to-cure" patients. Multiple patient- and virus-related factors that do not affect cure rates in treatment-naive patients may need to be considered in choosing a re-treatment regimen for these patients. These regimens may need to include combinations drugs that are not available in single-tablet form, addition of ribavirin, and longer durations of treatment than standard.
Language	English
Publishing date	2020-03-16
Publishing country	United States
Document type	Journal Article
ZDB-ID	2757767-3
ISSN	2328-8957
ISSN	2328-8957
DOI	10.1093/ofid/ofaa095
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS).

Wyles, David L / Kang, Minhee / Matining, Roy M / Murphy, Robert L / Peters, Marion G

Open forum infectious diseases

2023 Volume 10, Issue 3, Page(s) ofad115

Abstract: Background: Long-term outcome data after hepatitis C virus (HCV) treatment are limited, particularly for comparisons between persons with and without HIV.: Methods: A5320 was a prospective cohort study that enrolled participants within 12 months of ... ...

Abstract	Background: Long-term outcome data after hepatitis C virus (HCV) treatment are limited, particularly for comparisons between persons with and without HIV. Methods: A5320 was a prospective cohort study that enrolled participants within 12 months of completing HCV DAA therapy, with or without sustained virologic response (SVR). The primary end point was composite: time to death or development of a targeted diagnosis. Component outcomes (death and targeted diagnosis) and liver-related events were also analyzed. The effects of HIV serostatus, HIV RNA and CD4, and liver disease stage on the outcomes were assessed. Follow-up was designated for 5 years. Results: Three hundred thirty-two participants enrolled: 184 with HIV/HCV (130 SVR) and 148 with HCV (125 SVR). The primary analysis was dominated by targeted diagnoses. Increased rates of targeted diagnoses were seen in HCV-HIV/SVR compared with HCV/SVR ( Conclusions: HCV cure following therapy reduces subsequent development of new clinical events, supporting the use of SVR as a predictor for clinical outcomes. Despite HIV control, a significant decrease in incident events or mortality was not demonstrated for people with HIV who achieved SVR, suggesting that coinfection attenuates the beneficial impact of SVR. Research is needed to better define mechanisms accounting for the long-term negative impact of controlled HIV infection.
Language	English
Publishing date	2023-03-06
Publishing country	United States
Document type	Journal Article
ZDB-ID	2757767-3
ISSN	2328-8957
ISSN	2328-8957
DOI	10.1093/ofid/ofad115
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: CROI 2019: highlights of viral hepatitis.

Luetkemeyer, Anne F / Wyles, David L

Topics in antiviral medicine

2019 Volume 27, Issue 1, Page(s) 41–49

Abstract: At the 2019 Conference on Retroviruses and Opportunistic Infections (CROI), there was a major focus on hepatitis C virus (HCV) elimination and improving each component of the hepatitis C care cascade. Many interventions showed promising improvements in ... ...

Abstract	At the 2019 Conference on Retroviruses and Opportunistic Infections (CROI), there was a major focus on hepatitis C virus (HCV) elimination and improving each component of the hepatitis C care cascade. Many interventions showed promising improvements in diagnosis and linkage to care. Settings with robust access to direct-acting antivirals (DAAs) continue to demonstrate the role of HCV treatment as prevention. However, substantial barriers to accessing curative therapy remain. Reinfection after treatment presents an important barrier to elimination, particularly in some populations of men who have sex with men (MSM). MSM without HIV infection are at an elevated risk for sexual acquisition of HCV, and several studies reported HCV rates that were as high as those seen in MSM living with HIV. There was also a focus on HCV and HBV in pregnant women. Rates of HCV infection in women of child-bearing potential have increased, making prenatal diagnosis a priority. In the first study of HCV treatment during pregnancy, sofosbuvir/ledipasvir started at 28 weeks of gestation led to cure in 8 pregnant women. Hepatitis B virus (HBV)-active antiretrovirals are generally effective in suppressing HBV but have low rates of surface antigen loss despite long term treatment. Initial results from novel laboratory assessments of intrahepatic HBV viral infection events were presented, hopefully paving the way for more effective HBV treatment strategies to control and potentially cure HBV.
MeSH term(s)	Antiviral Agents/therapeutic use ; HIV Infections/complications ; HIV Infections/drug therapy ; Hepatitis B, Chronic/diagnosis ; Hepatitis B, Chronic/drug therapy ; Humans
Chemical Substances	Antiviral Agents
Language	English
Publishing date	2019-05-25
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2656632-1
ISSN	2161-5853 ; 2161-5861
ISSN (online)	2161-5853
ISSN	2161-5861
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Regimens for Patients Coinfected with Human Immunodeficiency Virus.

Wyles, David L

Clinics in liver disease

2015 Volume 19, Issue 4, Page(s) 689–706, vi–vii

Abstract: Hepatitis C virus (HCV) coinfection is prevalent in patients with human immunodeficiency virus (HIV) and has an accelerated disease course. Direct-acting antiviral (DAA) therapies that do not require interferon increase response rates to levels identical ...

Abstract	Hepatitis C virus (HCV) coinfection is prevalent in patients with human immunodeficiency virus (HIV) and has an accelerated disease course. Direct-acting antiviral (DAA) therapies that do not require interferon increase response rates to levels identical to those seen in HCV monoinfection. However, drug-drug interaction between antiretrovirals and HCV medication is the major consideration in deciding on the appropriate HCV therapeutic approach in patients with HIV. This article summarizes the currently available data with HCV DAAs in patients with HIV, and focuses on predicting and managing drug interaction to facilitate successful DAA-based HCV therapy in those with HIV.
MeSH term(s)	Anti-HIV Agents/therapeutic use ; Antiviral Agents/adverse effects ; Antiviral Agents/therapeutic use ; Coinfection/drug therapy ; Drug Interactions ; Drug Therapy, Combination ; HIV Infections/drug therapy ; Hepatitis C/drug therapy ; Humans ; Interferons/therapeutic use ; Nucleic Acid Synthesis Inhibitors/therapeutic use ; Polyethylene Glycols/therapeutic use ; Protease Inhibitors/therapeutic use ; RNA, Viral/biosynthesis ; Ribavirin/therapeutic use ; Sofosbuvir/therapeutic use ; Viral Nonstructural Proteins/antagonists & inhibitors
Chemical Substances	Anti-HIV Agents ; Antiviral Agents ; Nucleic Acid Synthesis Inhibitors ; Protease Inhibitors ; RNA, Viral ; Viral Nonstructural Proteins ; Polyethylene Glycols (3WJQ0SDW1A) ; Ribavirin (49717AWG6K) ; Interferons (9008-11-1) ; NS-5 protein, hepatitis C virus (EC 2.7.7.48) ; Sofosbuvir (WJ6CA3ZU8B)
Language	English
Publishing date	2015-08-29
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1472315-3
ISSN	1557-8224 ; 1089-3261
ISSN (online)	1557-8224
ISSN	1089-3261
DOI	10.1016/j.cld.2015.06.008
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Se 1870: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: CROI 2018: Highlights of Viral Hepatitis.

Luetkemeyer, Anne F / Wyles, David L

Topics in antiviral medicine

2018 Volume 26, Issue 1, Page(s) 30–38

Abstract: At the 2018 Conference on Retroviruses and Opportunistic Infections (CROI), there was a major focus on hepatitis C virus (HCV) elimination and improving each component of the hepatitis C care cascade. Several countries and cohorts have demonstrated the ... ...

Abstract	At the 2018 Conference on Retroviruses and Opportunistic Infections (CROI), there was a major focus on hepatitis C virus (HCV) elimination and improving each component of the hepatitis C care cascade. Several countries and cohorts have demonstrated the remarkable impact that universal HCV testing and unrestricted access to hepatitis C treatment can have on markedly reducing incident HCV infections and HCV infection prevalence, including in people who inject drugs and HIV/HCV-coinfected populations. However, in many settings, substantial barriers to widespread HCV treatment remain, including undiagnosed HCV infection, particularly in populations outside the standard "baby boomer" birth cohort (ie, born 1945-1965); restricted access to hepatitis C treatment in those with known HCV infection; reinfection with HCV; and migration of HCV-infected populations. Many innovative programs have successfully implemented HCV testing and treatment outside of traditional care settings, expanding access for harder-to-reach populations, which will be crucial to successful elimination efforts. Outbreaks of hepatitis A virus (HAV) infection continue to occur in among men who have sex with men and homeless populations in the United States, Europe, and Southeast Asia, highlighting the need for improved HAV vaccination programs for populations at risk.
MeSH term(s)	Antiviral Agents/therapeutic use ; Coinfection ; Congresses as Topic/trends ; Global Health ; HIV Infections/drug therapy ; Hepatitis C/drug therapy ; Hepatitis C/epidemiology ; Hepatitis C/prevention & control ; Humans ; Mass Screening/methods ; Prevalence
Chemical Substances	Antiviral Agents
Language	English
Publishing date	2018-05-03
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2656632-1
ISSN	2161-5853 ; 2161-5861
ISSN (online)	2161-5853
ISSN	2161-5861
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito